0913 GMT - AstraZeneca is among the most mentioned companies across news items over the past three hours, according to Factiva data, after the pharmaceutical giant reported results of its datopotamab deruxtecan lung-cancer treatment. The news was met with disappointment by the market, with shares falling as much as 6.2% in early trade and leading the FTSE 100-index fallers. They are currently down 5% at 10,726.0 pence. Astra said datopotamab deruxtecan met dual primary endpoint of progression-free survival in patients with advanced non-small cell lung cancer in a phase 3 trial. However, UBS analysts write that the benefit isn't quantified and Astra didn't call out clinical meaningfulness as it normally does. The trial isn't mature enough at this point for overall survival and some severe side effects were observed, they say. Dow Jones & Co. owns Factiva. (ian.walker@wsj.com)

(END) Dow Jones Newswires

July 03, 2023 05:28 ET (09:28 GMT)

Copyright (c) 2023 Dow Jones & Company, Inc.
AstraZeneca (NASDAQ:AZN)
Historical Stock Chart
Von Jun 2024 bis Jul 2024 Click Here for more AstraZeneca Charts.
AstraZeneca (NASDAQ:AZN)
Historical Stock Chart
Von Jul 2023 bis Jul 2024 Click Here for more AstraZeneca Charts.